About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Pharmacies Will Have Options ... and Costs
The FDA is trying to decide how to implement a new law by January 1, 2015, that requires manufacturers, wholesalers, and pharmacies to trace drug products as they move through the distribution chain. A degree of turmoil appears likely to result.
Health care professionals can use a variety of social media tools to improve or enhance networking, education, and other activities. However, these tools also present some potential risks, such as unreliable information and violations of patients’ privacy rights.
C. Lee Ventola
Defects in a single gene lead to the defective proteins that cause cystic fibrosis, making the disease an ideal candidate for mutation-targeted therapy. Although ivacaftor is currently the only FDA-approved CFTR modifier, others are in development.
Rebecca S. Pettit, PharmD, MBA, BCPS; and Chris Fellner
The American Society of Clinical Oncology meeting drew more than 34,600 people to Chicago to learn about the latest research, including studies on lymphoma, pancreatic cancer, colon cancer, melanoma, multiple myeloma, and palliative care.
As better drugs from a variety of pharmaceutical industry players enter a market with millions of untreated patients, U.S. spending on hepatitis C treatments is expected to rise from $2.1 billion in 2012 to $6.5 billion in 2022.
Kunj Gohil, PharmD, RPh
Ingestion or Aspiration of Foreign Objects or Toxic Substances Is Not Just a Safety Concern With Children
Take steps to prevent ingestion or aspiration of objects
Matthew Grissinger, RPh, FaScP
Congressional and Patient-Group Opposition to Other, More Controversial Part D Reforms Sank the Plan
FDA approvals, drug indications, and updates
Albiglutide (Tanzeum) for type-2 diabetes, ramucirumab (Cyramza) for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, and ceritinib (Zykadia) for metastatic non–small-cell lung cancer
Marvin M. Goldenberg, PhD, RPh, MS
Ibrutinib (Imbruvica): a novel targeted therapy for chronic lymphocytic leukemia
Sapna Parmar, PharmD; Khilna Patel, PharmD; and Javier Pinilla-Ibarz, MD, PhD